9 June 2022 - After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Document  on the use of roxadustat for the treatment of patients with anaemia associated with chronic kidney disease and submitted it to NICE.

Roxadustat is recommended as an option for treating symptomatic anaemia associated with chronic kidney disease (CKD) in adults only if:

• They have stage 3 to 5 chronic kidney disase with no iron deficiency and

• They are not on dialysis at the start of treatment and

• Astellas provides roxadustat according to the commercial arrangement

Read NICE Final Appraisal Document